Catalent signs agreement for first-in-class oncological therapy
Zumutor Biologics has chosen Catalent to provide process optimisation and drug substance manufacturing services
Breaking News
Horizon Discovery expands cell-based CRISPR screening services
Cell line engineering specialist has expanded its range to complement its T cell screening service
AstraZeneca joins forces with Silence to develop siRNA therapeutics
Collaboration with Silence Therapeutics has been agreed to develop small interfering RNA therapeutics that act inside ...
Dover acquires equipment supplier to expand biopharma presence
Dover has agreed to acquire flow measurement device manufacturer Em-tec and will integrate into its Pumps & Process ...
New technology in cell and gene therapies to meet patient needs
Angela Myers, Head of Gene Editing and Novel Modalities at Merck, outlines the challenges arising with the increasing ...
High-throughput technologies: a paradigm shift in biopharmaceutical development
The growing demand for innovative biopharmaceutical products is putting pressure on the pharmaceutical biotechnology ...
Tepnel Pharma Services takes first step towards employee ownership
The QC company's transition to employee-ownership has been set in motion to generate a reciprocal culture that is on ...
Medical cannabis made in Italy
Dr Fabio Di Francesco, a compounding pharmacist based in Rome, describes how cannabis is used in various dosage forms ...
WuXi completes weather-tight seal of Irish biologics facility
WuXi Biologics has completed the seal of its first global supply facility in Europe that began construction in February ...
FDA releases final guidance for upcoming biological product transition
The BPCI Act requires that a marketing application for a “biological product” must be submitted as a biologics ...
Supply and demand trends in the mammalian biomanufacturing industry
BDO-USA's Dawn M. Ecker, Director, bioTRAK Database Services, and Patricia Seymour, Managing Director, BioProcess ...
Future market dynamics and opportunities in immuno-oncology
Long-term survival, tumour-agnostic effects and the potential for cure in a fraction of patients are key catalysts ...
Better by design: the role of delivery device in biosimilar adoption
George I’ons of Owen Mumford Pharmaceutical Services analyses the uptake of new biosimilars and their advancing ...
Domain makes two acquisitions for G Protein-Coupled Receptor programme
Prestwick Chemical and Neurofit are former subsidiaries of Australia-based Bionomics
Bioprocess expert chooses PM Group to design training facility expansion
National Institute for Bioprocessing Research has chosen PM Group to develop a design to expand its existing facility ...
In Brief
Most Popular in Biotechnology
Featured Companies
Reports
